Evidence map›Paper›PMID 34210365›Full record

ArticleAlzheimer's research & therapy2021

Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia.

Katherine J Bangen, Denis S Smirnov, Lisa Delano-Wood, Christina E Wierenga, Mark W Bondi, David P Salmon, Douglas Galasko

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Arterial stiffness moderates the link between NfL and cognition: The IGNITE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Katherine J BangenResearch Service, VA San Diego Healthcare System, Building 13, 3350 La Jolla Village Drive (151A), San Diego, CA, 92161, USA. kbangen@ucsd.edu.ORCID 0000-0002-1363-3179
Denis S SmirnovMedical Scientist Training Program, University of California, San Diego, La Jolla, CA, USA.
Lisa Delano-WoodDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Christina E WierengaResearch Service, VA San Diego Healthcare System, Building 13, 3350 La Jolla Village Drive (151A), San Diego, CA, 92161, USA.
Mark W BondiDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
David P SalmonDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Douglas GalaskoDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
University of California San Diego · US

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAMES B BREWER · 2019 to 2026
$34.9M
New Quantitative Neuroimaging Metrics of Structural and Functional Connectivity of the Locus Coeruleus as a Novel Biomarker of Alzheimer's Disease Pathogenesis and ProgressionR01AG054049 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BONDI, MARK W, FRANK, LAWRENCE R · 2017 to 2021
$4.1M
Intracranial arterial compliance, cerebral blood flow, and dementia risk in older adults with type 2 diabetesR01AG063782 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BANGEN, KATHERINE · 2020 to 2024
$3.7M
Re-visiting Methods for MCI Diagnosis to Improve Biomarker and Trial FindingsR01AG049810 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BONDI, MARK W, EDLAND, STEVEN DYAL · 2016 to 2020
$3.7M
Cognitive and Brain Changes in Preclinical Alzheimer's DiseaseI01CX000565 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI WIERENGA, CHRISTINA E · 2013 to 2022
–
Cerebral arterial compliance, blood flow, and cognition in Veterans with diabetesI01CX001842 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BANGEN, KATHERINE · 2020 to 2023
–
CSRD VA I01 CX000565CSRD VA I01 CX001842NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG049810NIA NIH HHS R01 AG054049NIA NIH HHS R01 AG063782
6 · The paper itself

Abstract

backgroundArterial stiffening has emerged as an important risk factor for Alzheimer's disease (AD) and related dementias. Carotid-femoral pulse wave velocity has been proposed as a non-invasive and reproducible method to assess arterial stiffness. However, the association of pulse wave velocity with performance across multiple cognitive domains as well as interactions with in vivo AD biomarkers and apolipoprotein E (APOE) genotype has received limited study.

methodWe studied 193 older adult volunteers (167 with normal cognition and 26 with mild cognitive impairment) who underwent comprehensive medical and neuropsychological evaluation at the University of California, San Diego Alzheimer's Disease Research Center. Cerebrospinal fluid (CSF) biomarkers were available on 123 participants (63%). Linear models examined whether pulse wave velocity significantly interacted with APOE ε4 status and CSF AD biomarker positivity (based on the ratio of total tau over beta-amyloid [tau/Aβ

resultsAfter adjusting for demographic characteristics and vascular risk burden, across the entire sample, pulse wave velocity was associated with poorer executive functioning but not the performance in the other cognitive domains. When the modifying effects of AD genetic risk and CSF AD biomarkers were considered, pulse wave velocity interacted with APOE genotype and CSF tau/Aβ ratio such that a stronger association between elevated pulse wave velocity and poorer memory performance was found among those positive for CSF and genetic AD markers. There were no significant interaction effects for non-memory cognitive domains.

conclusionThe findings suggest that pulse wave velocity, a non-invasive method to assess arterial wall properties, may be a useful marker of risk for cognitive decline, particularly among individuals who are APOE ε4 carriers or CSF AD biomarke0r-positive.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EBiomarkersGenotypeHumansPeptide FragmentsPulse Wave Analysistau ProteinsAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EBiomarkersPeptide Fragmentstau ProteinsAgingAlzheimer’s diseaseArterial stiffeningCognitionMemoryMicrocirculationPulse wave velocityVascular risk factors

Identifiers

PMID34210365
PMCPMC8246656
OpenAlexW3174128876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.